Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Operating Expenses (2019 - 2026)

Enliven Therapeutics has reported Operating Expenses over the past 8 years, most recently at $27.8 million for Q1 2026.

  • Quarterly results put Operating Expenses at $27.8 million for Q1 2026, down 12.21% from a year ago — trailing twelve months through Mar 2026 was $115.8 million (up 5.01% YoY), and the annual figure for FY2025 was $119.7 million, up 14.45%.
  • Operating Expenses reached $27.8 million in Q1 2026 per ELVN's latest filing, down from $34.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $34.3 million in Q4 2025 and bottomed at $8.7 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $24.6 million (2024), compared with a mean of $22.0 million.
  • The largest annual shift saw Operating Expenses tumbled 31.54% in 2022 before it surged 123.64% in 2023.
  • Over 5 years, Operating Expenses stood at $10.2 million in 2022, then skyrocketed by 123.64% to $22.7 million in 2023, then grew by 18.33% to $26.9 million in 2024, then grew by 27.47% to $34.3 million in 2025, then decreased by 18.85% to $27.8 million in 2026.
  • Business Quant data shows Operating Expenses for ELVN at $27.8 million in Q1 2026, $34.3 million in Q4 2025, and $25.1 million in Q3 2025.